LOGIN  |  REGISTER
Cue Biopharma

Spok to Present and Host 1x1 Investor Meetings at the 35th Annual Piper Sandler & Co. Healthcare Conference

November 16, 2023 | Last Trade: US$17.68 0.29 1.67

ALEXANDRIA, Va. / Nov 16, 2023 / Business Wire / Spok Holdings, Inc. (NASDAQ: SPOK), a global leader in healthcare communications, today announced that Vincent D. Kelly, chief executive officer, will participate in the 35th annual Piper Sandler & Co. healthcare conference on November 29, 2023 in New York. The Company’s presentation is scheduled for 12:30 pm ET. Spok will also host a series of 1X1 meetings with investors on November 29, 2023.

The presentation will also be webcast and can be accessed via the conference presentation link, and in the investor relations section of the Company's website: http://www.spok.com.

About Spok

Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK), headquartered in Alexandria, Virginia, is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on the Spok Care Connect® platform to enhance workflows for clinicians and support administrative compliance. Our customers send over 70 million messages each month through their Spok® solutions. Spok enables smarter, faster clinical communication. For more information, visit spok.com.

Spok is a trademark of Spok Holdings, Inc. Spok Care Connect and Spok Mobile are trademarks of Spok, Inc.

Terns Pharmaceuticals

Stock Quote

Last Trade: US$17.68
Daily Change: 0.29 1.67
Daily Volume: 147,793
Market Cap: US$358.370M

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page